Sage Plans New Trials And Approval Timeline For Zuranolone

Company Will Explore A Higher Dose For The Antidepressant

 
• By Jessica Merrill

Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.

Curving path during sunset cutting through a panoramic view of rolling green hilss
Sage sees a longer, but straightforward path for zuranolone • Source: Shutterstock

More from Neurological

More from Therapy Areas